OTCMKTS:CSLLY - CSL Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$116.22
▼ -0.05 (-0.04%)
1 month | 3 months | 12 months
Get New CSL Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CSLLY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CSLLY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for CSL in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $116.22.

Hold

The current consensus among 5 investment analysts is to hold stock in CSL. This rating has held steady since April 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/16/2021MacquarieDowngradeOutperform ➝ Neutral
i
5/4/2021MacquarieUpgradeNeutral ➝ Outperform
i
3/23/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform
i
3/10/2021CitigroupUpgradeNeutral ➝ Buy
i
2/18/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral
i
1/27/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
i
1/21/2021CitigroupUpgradeNeutral ➝ Buy
i
11/11/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
i
8/20/2020CitigroupDowngradeBuy ➝ Neutral
i
Rating by John Deakin-Bell at Citigroup Inc.
5/28/2020CitigroupUpgradeNeutral ➝ Buy
i
4/14/2020CitigroupDowngradeBuy ➝ Neutral
i
4/9/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
i
3/13/2020Jefferies Financial GroupUpgradeHold ➝ Buy
i
3/13/2020CitigroupUpgradeNeutral ➝ Buy
i
2/18/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight
i
1/23/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
i
12/4/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
i
10/21/2019Jefferies Financial GroupInitiated CoverageBuy
i
(Data available from 6/16/2016 forward)
CSL logo
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Read More

Today's Range

Now: $116.22
$115.55
$117.00

50 Day Range

MA: $108.32
$100.83
$116.27

52 Week Range

Now: $116.22
$94.05
$117.98

Volume

35,696 shs

Average Volume

52,772 shs

Market Capitalization

$105.79 billion

P/E Ratio

50.31

Dividend Yield

0.81%

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of CSL?

The following sell-side analysts have issued stock ratings on CSL in the last twelve months: Citigroup Inc., Credit Suisse Group AG, JPMorgan Chase & Co., Macquarie, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for CSLLY.

What is the current price target for CSL?

0 Wall Street analysts have set twelve-month price targets for CSL in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for CSL in the next year.
View the latest price targets for CSLLY.

What is the current consensus analyst rating for CSL?

CSL currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CSLLY, but not buy more shares or sell existing shares.
View the latest ratings for CSLLY.

What other companies compete with CSL?

How do I contact CSL's investor relations team?

CSL's physical mailing address is 45 Poplar Road, Parkville C3, 3052. The company's listed phone number is 61-3-9389-1911 and its investor relations email address is [email protected] The official website for CSL is www.csl.com.au.